MX2022016590A - Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. - Google Patents

Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.

Info

Publication number
MX2022016590A
MX2022016590A MX2022016590A MX2022016590A MX2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A
Authority
MX
Mexico
Prior art keywords
dosing regimen
inflammatory bowel
bowel disease
treating inflammatory
induction
Prior art date
Application number
MX2022016590A
Other languages
English (en)
Inventor
Mina Hassan-Zahraee
Gang Li
Mary Lynn Baniecki
Kenneth Eugene Hung
Li Xi
Zhan Ye
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022016590A publication Critical patent/MX2022016590A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de la enfermedad inflamatoria intestinal (IBD) en un paciente, el método comprende administrar al paciente un anticuerpo anti-ligando 1A similar al TNF (TL1A) en un régimen de dosificación de inducción suficiente para mejorar los signos y síntomas de la IBD durante al menos 12 semanas después del inicio del tratamiento con el anticuerpo anti-TL1A, dicho régimen de dosificación de inducción comprende una pluralidad de dosis de inducción individuales, en el que el método además comprende administrar al paciente un régimen de dosificación de mantenimiento posterior después de completar el régimen de dosificación de inducción, dicho régimen de dosificación de mantenimiento comprende una pluralidad de dosis de mantenimiento individuales separadas entre sí por al menos 2 semanas.
MX2022016590A 2020-06-26 2021-06-23 Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. MX2022016590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044390P 2020-06-26 2020-06-26
PCT/IB2021/055546 WO2021260577A2 (en) 2020-06-26 2021-06-23 Methods of treating inflammatory bowel disease with tl1a antibodies

Publications (1)

Publication Number Publication Date
MX2022016590A true MX2022016590A (es) 2023-02-01

Family

ID=76730925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016590A MX2022016590A (es) 2020-06-26 2021-06-23 Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.

Country Status (9)

Country Link
US (1) US20230235070A1 (es)
EP (1) EP4171632A2 (es)
JP (1) JP2022022994A (es)
KR (1) KR20230025898A (es)
CN (1) CN116322762A (es)
BR (1) BR112022025667A2 (es)
CA (1) CA3187966A1 (es)
MX (1) MX2022016590A (es)
WO (1) WO2021260577A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012315474B2 (en) 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
PH12022550978A1 (en) 2019-10-24 2023-10-09 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CN118829653A (zh) * 2022-01-07 2024-10-22 普罗米修斯生物科学公司 用tl1a抑制剂和il23抑制剂的组合治疗炎性疾病的方法
AU2023314783A1 (en) 2022-07-27 2025-03-06 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
EP4665395A1 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
AU2024324300A1 (en) 2023-08-11 2026-02-12 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
US20250361311A1 (en) * 2024-05-24 2025-11-27 Xencor, Inc. Anti-tnf-like ligand 1a (tl1a) antibodies
CN118497088B (zh) * 2024-07-18 2024-10-01 北京大学人民医院 变异链球菌及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US9896511B2 (en) * 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20120238468A1 (en) * 2009-10-05 2012-09-20 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
AU2012315474B2 (en) * 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
MX2016002879A (es) * 2013-09-06 2016-08-17 Cedars Sinai Medical Center Sistemas, dispositivos y metodos para la terapia anti-tl1a.
AU2014348676B2 (en) * 2013-11-13 2020-06-18 Bristol-Myers Squibb Company Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2017201461A1 (en) * 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
CN110121509B (zh) * 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
MA52366A (fr) * 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
CA3121162A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith

Also Published As

Publication number Publication date
CN116322762A (zh) 2023-06-23
WO2021260577A2 (en) 2021-12-30
CA3187966A1 (en) 2021-12-30
KR20230025898A (ko) 2023-02-23
JP2022022994A (ja) 2022-02-07
US20230235070A1 (en) 2023-07-27
WO2021260577A3 (en) 2022-04-28
EP4171632A2 (en) 2023-05-03
BR112022025667A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2022016590A (es) Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.
RU2013120957A (ru) Способы лечения псориаза с использованием антагонистов il-17
Pan et al. Open randomized clinical trial on JWSJZ decoction for the treatment of ALS patients
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
RU2013110844A (ru) АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
RU2016108809A (ru) Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2025004670A (es) Metodos para tratar colestasis intrahepatica familiar progresiva
Lim et al. The role of intravenous immunoglobulin (IVIG) in reducing infection risk in multiple myeloma (MM) patients receiving Immune-Based Therapies: a Single Center experience
YU et al. Clinical observation of ruyi Jinhuang Powder combined with ICIs in the treatment of advanced liver cancer complicated with dampness and heat syndrome of liver and gallbladder
Chen Paths toward hepatitis B immunization in South Korea and Taiwan
CN104208670B (zh) 一种治疗乙肝的药物组合物
Fu et al. Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study
Laplaud et al. Recommendations for the management of multiple sclerosis relapses
Sadeghi et al. Immunotherapy of Prostate Cancer may Change mRNA Level of Virulence Factor Genes in E. Faecalis of Microflora
Palladini et al. AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
Ohara et al. Analysis of risk factors for lenalidomide-associated skin rash and desensitization protocol using prednisolone administration in patients with multiple myeloma
Barisic et al. Adie's pupil and ANNA-1 associated paraneoplastic neurologic syndromes predict complete response in limited-stage SCLC: a case report
Klein et al. Serum-derived Bovine Immunoglobulin Isolate: A New Medical Food for the Clinical Dietary Management of Enteropathy: 1881
Sethi et al. Inpatient Burden of Constipation in the United States: An Analysis of National Trends from 1997-2010: Presidential Poster: 1882
Costantini et al. Prulifloxacin vs Phosphomycin: Prophylaxis in patients with recurrent UTI. Preliminary results of a randomized multi-centre study
RU2011152664A (ru) Способ лечения пролиферативных заболеваний
Chiapparrone et al. Compliance with one year maintenance intravesical BCG in patients affected by t1g3 bladder cancer
Salem et al. 651 Bridges to Excellence (BTE) Quality Indicators in Inflammatory Bowel Disease (IBD) in Gastroenterology Fellows' Clinic at the University of Oklahoma Health Sciences Center: A Quality Improvement Project